Business
Tetra Bio-Pharma and Santé Cannabis Announce Completion of the First Phase 2 Cannabis Oil Trial in Cancer and Non-Cancer Patients
Tetra Bio-Pharma and Santé Cannabis Announce Completion of the First Phase 2 Cannabis Oil Trial in Cancer and Non-Cancer Patients.
About this update from Tetra Bio-pharma Inc.
[{"type":"text","content":"\nOTTAWA, March 04, 2019 (GLOBE NEWSWIRE) -- Tetra Bio-Pharma Inc. (\"Tetra\" or the \"Company\") (TSX-V: TBP) (OTCQB: TBPMF), a global leader in cannabinoid-derived drug development and discovery, is pleased to announce completion of the first double-blind, randomized and placebo-controlled Phase 2 clinical trial of cannabis oil capsules. The trial evaluated the safety and efficacy of different doses and ratios of medical cannabis oil comprised of THC and CBD, for the treatment of uncontrolled chronic pain in cancer and non-cancer patients.\n The Phase 2 trial was conducted by Montreal-based Santé Cannabis, Quebec's first clinical research organization specializing in cannabis and cannabinoids for medical purposes. Dr. Antonio Vigano, and his colleagues at Santé Cannabis, designed this study to obtain clinical data on the safety and potential efficacy of various cannabis oils used in the practice of medicine under the Cannabis regulations. During the next 3 months, Santé Cannabis will study the data and submit a scientific manuscript for publication addressing key outcomes from the trial: Safety and tolerability data, such as side effects, associated with the approach used in this study;Preliminary efficacy data on the three different ratios of THC and CBD used; andPreliminary data on the minimal effective dose of each cannabis oil. \"This study will provide evidence-based data on medical cannabis for chronic pain,\" said Dr. Antonio Vigano, Research Director of Santé Cannabis and McGill University Associate Professor in the Department of Oncology. \"For many patients, under careful monitoring, cannabis oil can potentially reduce or even eliminate the need for other pharmacological medications. The outcome of this study will support clinicians to better understand dosing and titration of medical cannabis in cancer and non-cancer patients. Our data will encourage researchers to pursue deeper studies to quantify real benefits and potential risks of natural cannabinoids as a complementary therapeutic approach across larger populations.\" According to Dr. Guy Chamberland, Tetra's CEO and CSO, \"This study is the first to investigate encapsulated medical cannabis oil for the management of chronic pain. The analysis of key outcomes will provide Tetra Bio-Pharma with importan...